Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.

Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW.

Prostate. 2013 Apr;73(5):455-66. doi: 10.1002/pros.22587. Epub 2012 Oct 4.

PMID:
23038103
2.

Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.

Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW.

Mol Cell Biol. 2010 Nov;30(22):5260-72. doi: 10.1128/MCB.00484-10. Epub 2010 Sep 20.

3.

ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW.

Cancer Res. 2010 Nov 15;70(22):9402-12. doi: 10.1158/0008-5472.CAN-10-1199. Epub 2010 Sep 23.

4.

Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.

Bohrer LR, Chen S, Hallstrom TC, Huang H.

Endocrinology. 2010 Nov;151(11):5136-45. doi: 10.1210/en.2010-0436. Epub 2010 Sep 29.

5.
6.

Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.

Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, Li JJ, Chen HW.

Mol Cancer Res. 2014 Apr;12(4):539-49. doi: 10.1158/1541-7786.MCR-13-0459. Epub 2014 Jan 3.

7.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
8.

Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Li H, Cai Q, Godwin AK, Zhang R.

Mol Cancer Res. 2010 Dec;8(12):1610-8. doi: 10.1158/1541-7786.MCR-10-0398. Epub 2010 Nov 29.

9.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

10.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.

Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.

11.

Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX, Chen HW.

Mol Cell Biol. 2012 Aug;32(15):3121-31. doi: 10.1128/MCB.00204-12. Epub 2012 May 29.

12.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

13.

Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer.

Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW.

Cancer Res. 2009 Apr 15;69(8):3339-46. doi: 10.1158/0008-5472.CAN-08-3440. Epub 2009 Mar 24.

14.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

15.

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.

Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H.

Oncotarget. 2015 Dec 1;6(38):41045-55. doi: 10.18632/oncotarget.5728.

16.

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.

Karanikolas BD, Figueiredo ML, Wu L.

Prostate. 2010 May 1;70(6):675-88. doi: 10.1002/pros.21112.

17.

Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.

Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, Kurokawa M.

Cancer Sci. 2014 May;105(5):512-9. doi: 10.1111/cas.12386. Epub 2014 Mar 30.

18.

Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.

Mukhopadhyay NK, Kim J, You S, Morello M, Hager MH, Huang WC, Ramachandran A, Yang J, Cinar B, Rubin MA, Adam RM, Oesterreich S, Di Vizio D, Freeman MR.

Oncogene. 2014 Jun 19;33(25):3235-45. doi: 10.1038/onc.2013.294. Epub 2013 Jul 29.

19.

Mutations and deletions of PRC2 in prostate cancer.

Jain P, Di Croce L.

Bioessays. 2016 May;38(5):446-54. doi: 10.1002/bies.201500162. Epub 2016 Mar 22. Review.

PMID:
27000413
20.

Polycomb repressive complex 2 regulates normal development of the mouse heart.

He A, Ma Q, Cao J, von Gise A, Zhou P, Xie H, Zhang B, Hsing M, Christodoulou DC, Cahan P, Daley GQ, Kong SW, Orkin SH, Seidman CE, Seidman JG, Pu WT.

Circ Res. 2012 Feb 3;110(3):406-15. doi: 10.1161/CIRCRESAHA.111.252205. Epub 2011 Dec 8.

Supplemental Content

Support Center